Tesamorelin
Tesamorelin, a synthetic peptide, is renowned for its potential to stimulate the production and release of growth hormone (GH). Specifically, it functions by mimicking the action of growth hormone-releasing hormone (GHRH) in the body. By binding to and activating the GHRH receptor, Tesamorelin triggers the secretion of GH from the pituitary gland. This surge in GH levels offers various benefits, including improvements in muscle mass, reduced adipose tissue, and enhanced metabolism. Additionally, Tesamorelin has shown promising results in clinical studies for its ability to manage excess visceral fat accumulation in individuals with HIV-associated lipodystrophy. Overall, Tesamorelin’s role in regulating growth hormone levels underscores its potential therapeutic applications in addressing various medical conditions related to growth hormone deficiency and metabolic disorders.
| Tesamorelin |
|
| CAS Number |
901758-09-6 |
| Molar Mass |
5146 g/mol |
| Molecular Formula |
C221H366N72O67S |
| Sequence |
Unk-Tyr-Ala-Asp-Ala-xiIle-Phe-xiThr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-xiIle-Met-Ser-Arg-Gln-Gln-Gly-Gln-Ser-Asn-Gln-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 |
What is Tesamorelin?
Tesamorelin is a synthetic peptide that mimics the growth hormone-releasing hormone (GHRH) naturally produced by the hypothalamus in the brain. With a molecular weight of 5146 g/mol, Tesamorelin was developed by Theratechnologies, a company based in Montreal, Canada, specifically to address lipodystrophy—a common condition among HIV-infected individuals.
In November 2010, the FDA approved Tesamorelin for the treatment of HIV-associated lipodystrophy. Clinical trials have demonstrated that Tesamorelin significantly reduces waist circumference and visceral adipose tissue (VAT) after 26 weeks of treatment. Extension phases of these trials confirmed that the improvements in VAT were maintained over time.
https://pubmed.ncbi.nlm.nih.gov/28832410/
Does Tesamorelin have the potential to reduce Abdominal Fat?
In a 2014 clinical trial, Tesamorelin administered for 6 months was associated with reductions in visceral fat and additionally with modest reductions in liver fat.
Disclaimer:
All products featured on this site are intended solely for research purposes and are not for human or animal consumption under any circumstances. These items should not be classified as drugs, foods, cosmetics, or medicinal products. By purchasing, the buyer assumes all associated risks and agrees to handle the products only as specified. Products should be administered by qualified professionals with the relevant expertise.
The distributor, manufacturer, and seller bear no responsibility for any misuse or subsequent outcomes arising from the use of these products. By completing and paying for your order, you agree to our Terms and Conditions and acknowledge that you will abide by these terms.
7 reviews for Tesamorelin 5mg